• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background

    Pericarditis Companies

    ID: MRFR/Pharma/1315-CR
    156 Pages
    Rahul Gotadki
    August 2019

    Pericarditis is a medical condition characterized by inflammation of the pericardium, the thin sac-like membrane surrounding the heart. This inflammation can lead to chest pain, fever, and other symptoms, making it a critical condition that requires prompt diagnosis and treatment.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Pericarditis Market

    Pericarditis Key Companies

     


    Latest Pericarditis Companies Update:

    R-Pharm International LLC announces positive Phase IIb results for CardiolRx: This investigational new drug for recurrent pericarditis demonstrates potential for long-term disease control and reduced risk of recurrence.


    Cardiol Therapeutics acquires PerImmune to advance development of CardiolRx: This acquisition strengthens CardiolRx's clinical development program and expands its focus on treating recurrent pericarditis.


    Abbott Laboratories partners with Inovio Pharmaceuticals to develop DNA vaccine for pericarditis: This collaboration aims to prevent pericarditis associated with viral infections or autoimmune diseases.


    List of Pericarditis Key companies in the market

    • Pfizer Inc.

    • AstraZeneca Plc

    • Novartis International AG

    • Allergan plc.

    • and Merck & Co., Inc.

    • Bayer AG

    • Reckitt Benckiser Group Plc.

    • PerkinElmer, Inc.

    • FUJIFILM Holdings Corporation

    • Sanofi

    • Johnson & Johnson Services